Synplogen and ginkgo bioworks announce plans to accelerate global dna manufacturing and gene therapy platform services in japan

Synplogen, a synthetic biology startup spun out of kobe university's graduate school of science, technology and innovation that provides custom dna synthesis and gene therapy biofoundry™ services, has entered into a non-binding memorandum of understanding ("mou") with ginkgo bioworks with the intent to advance global dna manufacturing and gene therapy platform services within the japanese market synplogen intends to support and introduce ginkgo's gene therapy services within the japanese biotechnology and pharmaceutical ecosystem kobe, japan and boston , dec. 6, 2023 /prnewswire/ -- synplogen co., a synthetic biology startup spun out of kobe university's graduate school of science, technology and innovation that provides custom dna synthesis and gene therapy biofoundry services, and ginkgo bioworks (nyse: dna), which is building the leading platform for cell programming and biosecurity, today announced that they have entered into a non-binding memorandum of understanding ("mou"). together, synplogen and ginkgo intend to accelerate the global development of dna manufacturing and gene therapy platform services in japan.
DNA Ratings Summary
DNA Quant Ranking